Assessment of choloroquine single dose treatment of malaria due to Plasmodium vivax in brazilian
Pinto, Ana Yecê das Neves
Azevedo, Carolina Heitmann
Silva, Janaína Bezerra da
Souza, José Maria de
Malaria regions of the Amazon basin have been characterized by difficult access and non-compliance of the patients to treatment. In an attempt to assess the schizonticide efficacy of chloroquine in a single dose of 600 mg, the authors realized a double-blind, placebo-controlled trial in 132 outpatients with vivax malaria. Patients were distributed into two groups: group CPLA, given chloroquine 600 mg (single dose) on the first day of treatment, and two doses of placebo on second and third days. Group CHLO, given chloroquine 600 mg on first day and 450 mg on second and third day. Geometric means of the parasite density during the follow-up was similar in both groups. No differences were observed in the parasitological cure between the two groups (p = 0.442). There was clinical and parasitological efficacy in treatment of patients given a single-dose of chloroquine. This suggests that its restricted use could be indicated in remote areas of Brazilian Amazon Region, nevertheless the inadequate response of three patients indicates the need for further studies.
xmlui.dri2xhtml.METS-1.0.item-citationPINTO, Ana Yecê das Neves et al. Assessment of choloroquine single dose treatment of malaria due to Plasmodium vivax in brazilian. Revista do Instituto de Medicina Tropical de São Paulo, v. 45, n. 6, p. 327-331, Nov.-Dec. 2003.
xmlui.dri2xhtml.METS-1.0.item-decsPrimaryMalária Vivax / terapia
Cloroquina / uso terapêutico